-
1
-
-
1542316127
-
Hepatitis B virus infection - Natural history and clinical consequences
-
15014185 10.1056/NEJMra031087 1:CAS:528:DC%2BD2cXitV2qurs%3D
-
Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350:1118-29.
-
(2004)
N Engl J Med
, vol.350
, pp. 1118-1129
-
-
Ganem, D.1
Prince, A.M.2
-
2
-
-
0030707941
-
Virus infection
-
9392700 10.1056/NEJM199712113372406 1:STN:280:DyaK1c%2FktFyjtA%3D%3D
-
Lee WM, Hepatitis B. Virus infection. N Engl J Med. 1997;337:1733-45.
-
(1997)
N Engl J Med
, vol.337
, pp. 1733-1745
-
-
Lee, W.M.1
Hepatitis, B.2
-
3
-
-
33644818518
-
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
-
16525137 10.1056/NEJMoa051285 1:CAS:528:DC%2BD28XitFWms7Y%3D
-
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-10.
-
(2006)
N Engl J Med
, vol.354
, pp. 1001-1010
-
-
Chang, T.T.1
Gish, R.G.2
De Man, R.3
Gadano, A.4
Sollano, J.5
Chao, Y.C.6
-
4
-
-
0033592764
-
Lamivudine as initial treatment for chronic hepatitis B in the United States
-
10528035 10.1056/NEJM199910213411702 1:CAS:528:DyaK1MXnt1Cqs78%3D
-
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-63.
-
(1999)
N Engl J Med
, vol.341
, pp. 1256-1263
-
-
Dienstag, J.L.1
Schiff, E.R.2
Wright, T.L.3
Perrillo, R.P.4
Hann, H.W.5
Goodman, Z.6
-
5
-
-
0037468406
-
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B
-
12606734 10.1056/NEJMoa021812 1:CAS:528:DC%2BD3sXhsFKju7w%3D
-
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-7.
-
(2003)
N Engl J Med
, vol.348
, pp. 800-807
-
-
Hadziyannis, S.J.1
Tassopoulos, N.C.2
Heathcote, E.J.3
Chang, T.T.4
Kitis, G.5
Rizzetto, M.6
-
6
-
-
0032499913
-
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
-
9654535 10.1056/NEJM199807093390201 1:CAS:528:DyaK1cXkvVSqtbY%3D
-
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8.
-
(1998)
N Engl J Med
, vol.339
, pp. 61-68
-
-
Lai, C.L.1
Chien, R.N.2
Leung, N.W.3
Chang, T.T.4
Guan, R.5
Tai, D.I.6
-
7
-
-
37349120537
-
Telbivudine versus lamivudine in patients with chronic hepatitis B
-
18094378 10.1056/NEJMoa066422 1:CAS:528:DC%2BD2sXhsVKht7nF
-
Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576-88.
-
(2007)
N Engl J Med
, vol.357
, pp. 2576-2588
-
-
Lai, C.L.1
Gane, E.2
Liaw, Y.F.3
Hsu, C.W.4
Thongsawat, S.5
Wang, Y.6
-
8
-
-
33644822860
-
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
-
16525138 10.1056/NEJMoa051287 1:CAS:528:DC%2BD28XitFWlsrY%3D
-
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-20.
-
(2006)
N Engl J Med
, vol.354
, pp. 1011-1020
-
-
Lai, C.L.1
Shouval, D.2
Lok, A.S.3
Chang, T.T.4
Cheinquer, H.5
Goodman, Z.6
-
9
-
-
0037468421
-
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
-
12606735 10.1056/NEJMoa020681 1:CAS:528:DC%2BD3sXhsFKisrc%3D
-
Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16.
-
(2003)
N Engl J Med
, vol.348
, pp. 808-816
-
-
Marcellin, P.1
Chang, T.T.2
Lim, S.G.3
Tong, M.J.4
Sievert, W.5
Shiffman, M.L.6
-
10
-
-
57349095400
-
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
-
19052126 10.1056/NEJMoa0802878 1:CAS:528:DC%2BD1cXhsVCrurjL
-
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-55.
-
(2008)
N Engl J Med
, vol.359
, pp. 2442-2455
-
-
Marcellin, P.1
Heathcote, E.J.2
Buti, M.3
Gane, E.4
De Man, R.A.5
Krastev, Z.6
-
11
-
-
4644295202
-
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
-
15382125
-
Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883-91.
-
(2004)
Hepatology
, vol.40
, pp. 883-891
-
-
Di Marco, V.1
Marzano, A.2
Lampertico, P.3
Andreone, P.4
Santantonio, T.5
Almasio, P.L.6
-
12
-
-
0041742409
-
Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop
-
12867754 10.1159/000071457 1:CAS:528:DC%2BD3sXntFyqsbo%3D
-
Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, et al. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology. 2003;46:164-70.
-
(2003)
Intervirology
, vol.46
, pp. 164-170
-
-
Suzuki, Y.1
Arase, Y.2
Ikeda, K.3
Saitoh, S.4
Tsubota, A.5
Suzuki, F.6
-
13
-
-
0029037074
-
The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes
-
7745682 1:CAS:528:DyaK2MXls1yitrw%3D
-
Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69:3350-7.
-
(1995)
J Virol
, vol.69
, pp. 3350-3357
-
-
Newbold, J.E.1
Xin, H.2
Tencza, M.3
Sherman, G.4
Dean, J.5
Bowden, S.6
-
14
-
-
0025329760
-
In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway
-
2155510 10.1016/0042-6822(90)90206-7 1:CAS:528:DyaK3cXhsFGjs74%3D
-
Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology. 1990;175:255-61.
-
(1990)
Virology
, vol.175
, pp. 255-261
-
-
Wu, T.T.1
Coates, L.2
Aldrich, C.E.3
Summers, J.4
Mason, W.S.5
-
15
-
-
13844250599
-
New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA
-
15710212 10.1016/j.jhep.2004.12.015
-
Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42:302-8.
-
(2005)
J Hepatol
, vol.42
, pp. 302-308
-
-
Zoulim, F.1
-
16
-
-
2942532722
-
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
-
15188170 10.1053/j.gastro.2004.03.018 1:CAS:528:DC%2BD2cXlsFaqs78%3D
-
Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750-8.
-
(2004)
Gastroenterology
, vol.126
, pp. 1750-1758
-
-
Werle-Lapostolle, B.1
Bowden, S.2
Locarnini, S.3
Wursthorn, K.4
Petersen, J.5
Lau, G.6
-
17
-
-
33748929265
-
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
-
16941693 10.1002/hep.21282 1:CAS:528:DC%2BD28XhtVeqt7bM
-
Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675-84.
-
(2006)
Hepatology
, vol.44
, pp. 675-684
-
-
Wursthorn, K.1
Lutgehetmann, M.2
Dandri, M.3
Volz, T.4
Buggisch, P.5
Zollner, B.6
-
18
-
-
75449107726
-
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
-
20049753 10.1002/hep.23327 1:CAS:528:DC%2BC3cXisVGgurs%3D
-
Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-30.
-
(2010)
Hepatology
, vol.51
, pp. 422-430
-
-
Chang, T.T.1
Lai, C.L.2
Kew Yoon, S.3
Lee, S.S.4
Coelho, H.S.5
Carrilho, F.J.6
-
19
-
-
72949113706
-
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
-
19622117 10.1111/j.1365-2893.2009.01146.x 1:STN:280: DC%2BC3c%2FhtVGnsg%3D%3D
-
Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17:16-22.
-
(2010)
J Viral Hepat
, vol.17
, pp. 16-22
-
-
Gish, R.G.1
Chang, T.T.2
Lai, C.L.3
De Man, R.4
Gadano, A.5
Poordad, F.6
-
20
-
-
78650477355
-
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
-
20955704 10.1053/j.gastro.2010.10.011 1:CAS:528:DC%2BC3cXhsFyltLvF
-
Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132-43.
-
(2011)
Gastroenterology
, vol.140
, pp. 132-143
-
-
Heathcote, E.J.1
Marcellin, P.2
Buti, M.3
Gane, E.4
De Man, R.A.5
Krastev, Z.6
-
21
-
-
34548216805
-
Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine
-
17705186 10.1002/jmv.20994 1:CAS:528:DC%2BD2sXhtVygu7nF
-
Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol. 2007;79:1472-7.
-
(2007)
J Med Virol
, vol.79
, pp. 1472-1477
-
-
Kobayashi, M.1
Suzuki, F.2
Akuta, N.3
Hosaka, T.4
Sezaki, H.5
Yatsuji, H.6
-
22
-
-
58649096155
-
2-Year GLOBE trial results: Telbivudine Is superior to lamivudine in patients with chronic hepatitis B
-
19027013 10.1053/j.gastro.2008.10.026 1:CAS:528:DC%2BD1MXislOhtLs%3D
-
Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-95.
-
(2009)
Gastroenterology
, vol.136
, pp. 486-495
-
-
Liaw, Y.F.1
Gane, E.2
Leung, N.3
Zeuzem, S.4
Wang, Y.5
Lai, C.L.6
-
23
-
-
79951669706
-
Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
-
21112655 10.1016/j.jhep.2010.07.046 1:CAS:528:DC%2BC3MXit1yqtbs%3D
-
Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011;54:449-54.
-
(2011)
J Hepatol
, vol.54
, pp. 449-454
-
-
Reijnders, J.G.1
Rijckborst, V.2
Sonneveld, M.J.3
Scherbeijn, S.M.4
Boucher, C.A.5
Hansen, B.E.6
-
24
-
-
48549107919
-
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
-
18585385 10.1053/j.gastro.2008.05.031 1:CAS:528:DC%2BD1cXhtVCqsL%2FK
-
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459-67.
-
(2008)
Gastroenterology
, vol.135
, pp. 459-467
-
-
Buster, E.H.1
Flink, H.J.2
Cakaloglu, Y.3
Simon, K.4
Trojan, J.5
Tabak, F.6
-
25
-
-
70350475693
-
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: Results of a long-term follow-up study in chronic hepatitis B patients
-
19584831 10.1038/ajg.2009.371 1:CAS:528:DC%2BD1MXht1Wrtr%2FI
-
Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, et al. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. Am J Gastroenterol. 2009;104:2449-57.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 2449-2457
-
-
Buster, E.H.1
Flink, H.J.2
Simsek, H.3
Heathcote, E.J.4
Sharmila, S.5
Kitis, G.E.6
-
26
-
-
66449121130
-
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
-
e2161-64
-
Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136:2169-79, e2161-64.
-
(2009)
Gastroenterology
, vol.136
, pp. 2169-2179
-
-
Marcellin, P.1
Bonino, F.2
Lau, G.K.3
Farci, P.4
Yurdaydin, C.5
Piratvisuth, T.6
-
27
-
-
65449123444
-
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
-
19115222 10.1002/hep.22744 1:CAS:528:DC%2BD1MXkslSqu7k%3D
-
Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49:1151-7.
-
(2009)
Hepatology
, vol.49
, pp. 1151-1157
-
-
Moucari, R.1
Mackiewicz, V.2
Lada, O.3
Ripault, M.P.4
Castelnau, C.5
Martinot-Peignoux, M.6
-
28
-
-
33847410055
-
Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: A clue from serum HBsAg levels
-
17503750 1:CAS:528:DC%2BD2sXjs1Gnt7w%3D
-
Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther. 2007;12:73-82.
-
(2007)
Antivir Ther
, vol.12
, pp. 73-82
-
-
Manesis, E.K.1
Hadziyannis, E.S.2
Angelopoulou, O.P.3
Hadziyannis, S.J.4
-
29
-
-
77956592924
-
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients
-
20931556 10.1002/hep.23905 1:CAS:528:DC%2BC3cXhsFOnsrrO
-
Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611-20.
-
(2010)
Hepatology
, vol.52
, pp. 1611-1620
-
-
Wursthorn, K.1
Jung, M.2
Riva, A.3
Goodman, Z.D.4
Lopez, P.5
Bao, W.6
-
30
-
-
0037062129
-
Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls
-
12020548 10.1016/S0140-6736(02)08594-X
-
Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686-9.
-
(2002)
Lancet
, vol.359
, pp. 1686-1689
-
-
Pocock, S.J.1
Clayton, T.C.2
Altman, D.G.3
-
31
-
-
77249123832
-
Is response to antiviral treatment influenced by hepatitis B virus genotype?
-
20137824 10.1016/j.jhep.2009.12.014 1:CAS:528:DC%2BC3cXisFejt78%3D
-
Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol. 2010;52:441-9.
-
(2010)
J Hepatol
, vol.52
, pp. 441-449
-
-
Raimondi, S.1
Maisonneuve, P.2
Bruno, S.3
Mondelli, M.U.4
-
32
-
-
20144388883
-
Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan
-
15779048 10.1002/jmv.20320
-
Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol. 2005;76:33-9.
-
(2005)
J Med Virol
, vol.76
, pp. 33-39
-
-
Suzuki, Y.1
Kobayashi, M.2
Ikeda, K.3
Suzuki, F.4
Arfase, Y.5
Akuta, N.6
-
33
-
-
33749239084
-
Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan
-
16956789 10.1016/j.hepres.2006.06.001 1:CAS:528:DC%2BD28XhtVGhs7%2FE
-
Sugauchi F, Orito E, Ohno T, Tanaka Y, Ozasa A, Kang JH, et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res. 2006;36:107-14.
-
(2006)
Hepatol Res
, vol.36
, pp. 107-114
-
-
Sugauchi, F.1
Orito, E.2
Ohno, T.3
Tanaka, Y.4
Ozasa, A.5
Kang, J.H.6
-
34
-
-
34347327007
-
Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
-
17596838 10.1002/jmv.20935 1:CAS:528:DC%2BD2sXotl2kt7Y%3D
-
Hou J, Schilling R, Janssen HLA, Hansen BE, Heijtink R, Sablon E, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol. 2007;79:1055-63.
-
(2007)
J Med Virol
, vol.79
, pp. 1055-1063
-
-
Hou, J.1
Schilling, R.2
Janssen, H.L.A.3
Hansen, B.E.4
Heijtink, R.5
Sablon, E.6
-
35
-
-
0037235229
-
Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD motif mutant and risk of breakthrough hepatitis - An open-cohort study
-
12480565 10.1016/S0168-8278(02)00335-5 1:CAS:528:DC%2BD38XptlSqtLs%3D
-
Akuta N, Tsubota A, Suzuki F, Suzuki Y, Hosaka T, Someya T, et al. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis - an open-cohort study. J Hepatol. 2003;38:91-7.
-
(2003)
J Hepatol
, vol.38
, pp. 91-97
-
-
Akuta, N.1
Tsubota, A.2
Suzuki, F.3
Suzuki, Y.4
Hosaka, T.5
Someya, T.6
-
36
-
-
0033844153
-
Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B
-
10960456 10.1053/jhep.2000.9717 1:CAS:528:DC%2BD3cXmsF2mu7w%3D
-
Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology. 2000;32:604-9.
-
(2000)
Hepatology
, vol.32
, pp. 604-609
-
-
Liaw, Y.F.1
Tsai, S.L.2
Chien, R.N.3
Yeh, C.T.4
Chu, C.M.5
-
37
-
-
27444446933
-
Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy
-
15923670 10.1136/gut.2004.062208 1:STN:280:DC%2BD2MrltVejsg%3D%3D
-
Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut. 2005;54:1604-9.
-
(2005)
Gut
, vol.54
, pp. 1604-1609
-
-
Flink, H.J.1
Sprengers, D.2
Hansen, B.E.3
Van Zonneveld, M.4
De Man, R.A.5
Schalm, S.W.6
-
38
-
-
0034761964
-
Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?
-
11679974 10.1053/jhep.2001.28459 1:CAS:528:DC%2BD3MXotlyqsbk%3D
-
Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology. 2001;34:1021-6.
-
(2001)
Hepatology
, vol.34
, pp. 1021-1026
-
-
Nair, S.1
Perrillo, R.P.2
|